Athenex dis­clos­es pa­tient death, clin­i­cal hold on CAR-NKT tri­al as it seeks strate­gic al­ter­na­tives

A neu­rob­las­toma pa­tient has died af­ter re­ceiv­ing Athenex’s nat­ur­al killer cell ther­a­py, trig­ger­ing a clin­i­cal hold, the com­pa­ny re­vealed.

Bay­lor Col­lege of Med­i­cine, which is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.